[Disease by CMV resistant to Ganciclovir. Should plasma valganciclovir levels be monitored in high risk patients?].
Sola
E
E
Vega
E
E
Gutiérrez
C
C
López
V
V
Cabello
M
M
Burgos
D
D
González Molina
M
M
Siles
J
J
D000998:Antiviral Agents / Q000008:administration & dosage / Q000097:blood* / Q000627:therapeutic use; D003587:Cytomegalovirus / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification; D003586:Cytomegalovirus Infections / Q000097:blood / Q000188:drug therapy* / Q000635:transmission; D016903:Drug Monitoring; D024921:Drug Resistance, Multiple, Viral / Q000235:genetics; D005260:Female; D017245:Foscarnet / Q000627:therapeutic use; D015774:Ganciclovir / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use; D005753:Gastric Mucosa / Q000821:virology; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000009:adverse effects*; D020125:Mutation, Missense; D017853:Phosphotransferases (Alcohol Group Acceptor) / Q000235:genetics / Q000502:physiology; D011183:Postoperative Complications / Q000097:blood / Q000188:drug therapy*; D012306:Risk; D000077562:Valganciclovir; D019562:Viral Load
D000998:Antiviral Agents; D016756:Immunoglobulins, Intravenous; D017245:Foscarnet; D017853:Phosphotransferases (Alcohol Group Acceptor); C075365:ganciclovir kinase; D000077562:Valganciclovir; D015774:Ganciclovir